Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IPH 2101

Monoclonal antibody · Antagonist of killer cell immunoglobulin-like receptor (KIR) · developed by Innate Pharma

Phase 2 Most advanced trial (none active)
IPHA Developer
2 Registered trials

What is IPH 2101?

IPH 2101 is a human monoclonal antibody that binds the inhibitory killer immunoglobulin-like receptor (KIR) on natural killer (NK) cells. By blocking KIR-mediated inhibition, it is intended to permit NK cell-mediated cytotoxicity against tumor cells. It is studied in multiple myeloma and smoldering multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
killer cell immunoglobulin-like receptor (KIR)
Mechanism
Antagonist of killer cell immunoglobulin-like receptor (KIR)
Pathways
NK cell-mediated cytotoxicity
Therapy area
Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5Q686XLG8L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01222286 Phase 2 Smoldering Multiple Myeloma Completed IPHA
NCT01217203 Phase 1 Patients With Multiple Myeloma Experiencing a Completed IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

First or Second RelapsePatients With Multiple Myeloma Experiencing aSmoldering Multiple Myeloma

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind IPH 2101

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.